Literature DB >> 11535002

Gerstmann-Sträussler-Scheinker syndrome,fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies.

S Collins1, C A McLean, C L Masters.   

Abstract

Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI) and kuru constitute major human prion disease phenotypes. Each has been successfully transmitted in animal models and all are invariably fatal neurodegenerative disorders, with the brains of affected individuals harbouring variable amounts of an abnormal, protease-resistant form of the prion protein (PrPres), which is inextricably linked to pathogenesis and transmissibility. Classical sporadic CJD is the most common human transmissible spongiform encephalopathy (TSE), but recently the variant form (vCJD), first described in the UK in 1996, has drawn considerable attention. In contrast to sporadic CJD, FFI and GSS are almost invariably genetically determined TSEs, caused by a range of mutations within the open reading frame of the prion protein gene (PRNP) on chromosome 20. By definition, the nosologic term FFI is reserved for patients manifesting prominent insomnia, generally in combination with dysautonomia, myoclonus, and eventual dementia, with the predominant pathologic changes lying within the thalami and a specific underlying mutation in PRNP. GSS, however, encompasses a more diverse clinical spectrum ranging from progressive cerebellar ataxia or spastic paraparesis (both usually in combination with dementia), to isolated cognitive impairment resembling Alzheimer's disease. Additional extra-pyramidal features, which may respond to dopaminergic therapy can also be seen. Neuropathological findings are also relatively diverse, partly overlapping with those found in Alzheimer's disease, especially the presence of neurofibrillary tangles (NFTs). Although GSS and FFI in their classical forms are differentiable clinical profiles, such divisions may have no intrinsic biological validity given the considerable intra-familial clinico-pathological diversity so commonly seen. Kuru constitutes a horizontally transmitted prion disease, which after a lengthy incubation period, presents clinically as a progressive cerebellar ataxia associated with tremors. It has now almost disappeared since the cessation of ritualistic endocannibalism in the late 1950s but was previously exclusively endemic amongst the Fore linguistic group and neighbouring tribes in the Eastern Highlands of New Guinea. Uniform topographical central nervous system histopathology includes spongiform change and neuronal loss, with amyloid (kuru) plaques in approximately 75% of cases. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11535002     DOI: 10.1054/jocn.2001.0919

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  39 in total

Review 1.  Genetic PrP Prion Diseases.

Authors:  Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

2.  Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome.

Authors:  W J Lukiw; P Dua; A I Pogue; C Eicken; J M Hill
Journal:  J Toxicol Environ Health A       Date:  2011

3.  Case 8: absentminded and "walking like a drunk".

Authors:  Matthew A Joenig; Justin McArthur
Journal:  MedGenMed       Date:  2005-02-03

4.  Fatal familial insomnia (FFI) complicated by posterior reversible encephalopathy syndrome (PRES).

Authors:  T Froböse; H Förstl; A Förschler
Journal:  Clin Neuroradiol       Date:  2013-10-19       Impact factor: 3.649

5.  In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET.

Authors:  Nobuyuki Okamura; Yusei Shiga; Shozo Furumoto; Manabu Tashiro; Yoshio Tsuboi; Katsutoshi Furukawa; Kazuhiko Yanai; Ren Iwata; Hiroyuki Arai; Yukitsuka Kudo; Yasuhito Itoyama; Katsumi Doh-ura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

Review 6.  Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature.

Authors:  Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

7.  Cytoplasmic prion protein induces forebrain neurotoxicity.

Authors:  Xinhe Wang; Stephanie L Bowers; Fei Wang; Xin-An Pu; Randy J Nelson; Jiyan Ma
Journal:  Biochim Biophys Acta       Date:  2009-03-10

8.  Role of proteolytic activation of protein kinase Cδ in the pathogenesis of prion disease.

Authors:  Dilshan S Harischandra; Naveen Kondru; Dustin P Martin; Arthi Kanthasamy; Huajun Jin; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

9.  Loss of anti-Bax function in Gerstmann-Sträussler-Scheinker syndrome-associated prion protein mutants.

Authors:  Julie Jodoin; Micheal Misiewicz; Priya Makhijani; Paresa N Giannopoulos; Jennifer Hammond; Cynthia G Goodyer; Andréa C LeBlanc
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

Review 10.  Drosophila melanogaster as a model organism of brain diseases.

Authors:  Astrid Jeibmann; Werner Paulus
Journal:  Int J Mol Sci       Date:  2009-02-02       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.